Mark Stejbach compensation by year
Alkermes Summary Compensation Table · the one fiscal year held| Component | FY2018 |
|---|---|
| Salary | $445,195 |
| Bonus | $0 |
| Stock awards | $908,010 |
| Option awards | $1,849,438 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $936,699 |
| Total | $4,139,342 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Alkermes plc. DEF 14A filed April 5, 2019, accession 0001564590-19-010920, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Alkermes plc. filed document, accession 0001564590-19-010920. Every figure is read from that document and cited to the page and table it appears in. Filed April 5, 2019.
Alkermes’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Richard Pops | Chairman and Chief Executive Officer | $17,055,802 |
| James Robinson | Former President and Chief Operating Officer | $6,727,868 |
| Mark Stejbach · this page | Former Senior Vice President and Chief Commercial Officer (3) | $4,139,342 |
| Kathryn Biberstein | Former Executive Vice President, Chief Compliance Officer, Chief Administrative Officer and Chief Risk Officer (2) | $4,115,634 |
| Craig Hopkinson | Senior Vice President of Medicines Development and Medical Affairs, and Chief Medical Officer | $3,791,198 |
| James Frates | Senior Vice President, Chief Financial Officer | $3,616,930 |
| David Gaffin | Senior Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $3,596,198 |
The full Alkermes compensation record
free company briefThis page is one person within Alkermes's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Alkermes proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Alkermes's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.